Summary:
In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c, TIR, TyG), reduced body weight and WHtR compared to standard care/placebo, though it was associated with minor gastrointestinal side effects.
| PICO | Description |
|---|---|
| Population | Adults diagnosed with type 2 diabetes mellitus (T2DM). |
| Intervention | Ebenatide treatment for 24 weeks. |
| Comparison | Standard care or placebo. |
| Outcome | Ebenatide significantly reduced HbA1c, improved time-in-range (TIR) and triglyceride-glucose index (TyG), and decreased body weight and waist-to-height ratio (WHtR) after 24 weeks. These benefits were sustained for at least 52 weeks, with mild gastrointestinal side effects reported. |
Source: Cheng-Lan Xu, et al. “Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.” Read article here.
